Price TH (2015), Blood (Link to abstract)
Granulocyte transfusion therapy has been used for 20 years without demonstrating clear efficacy in treating infections in neutropenic patients. This report from a multicenter randomized controlled trial included patients with neutropenia and proven/probable/presumed infection. Subjects were randomized to receive either standard antimicrobial therapy (n=56) or standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone (n=58). The primary end point was a composite of survival plus response to antimicrobials, at 42 days after randomization. Transfused subjects received a median of 5 transfusions. Overall success rates were 42% and 43% for the granulocyte and control groups, respectively (P > .99), and 49% and 41%, respectively, for subjects who received their assigned treatments (P = .64). Success rates for granulocyte and control arms did not differ within any infection
* There is no evidence for superiority of giving granulocyte transfusions in addition to standard care with antimicrobials in subjects with neutropenia and infection.